期刊文献+

HPV16L1E7的基因克隆及其在大肠杆菌中的表达 被引量:2

Cloning and expression of human papillomavirus type16L1E7in E.coli
在线阅读 下载PDF
导出
摘要 目的:研究人乳头瘤病毒(HPV)的主要衣壳蛋白L1和主要的转化蛋白E7的融合基因在原核细胞中的表达,为研制HPV16L1E7疫苗和诊断试剂盒提供依据。方法:采用聚合酶链反应(PCR)以重组质粒pUC19L1E7为模板扩增HPV16L1E7基因片段,克隆至载体pMD18-T中,并用限制性内切酶将HPV16L1E7基因切下,克隆至原核表达质粒pQE30中,经IPTG诱导表达,再使用SDS-PAGE和蛋白印迹检测其抗原性和表达水平。结果:HPV16L1E7融合蛋白能被抗HPV16L1抗体识别,分子量为66KD,经IPTG诱导4h后,表达的HPV16L1E7融合蛋白占菌体总蛋白量的25%以上。结论:成功构建的表达载体pOE30-L1E7可在原核表达细胞中高效表达,且表达出的HPV16L1E7融合蛋白具有反应活性,可与HPV16抗体发生反应。 Objective:To study the expression of fusion protein of HPV16capsid protein L1and transforming protein E7in E.coli.Methods :HPV16L1E7DNA fragment was amplified by poly-merase chain reaction from recombinant pUC19L1E7,the fragment was then cloned into the pMD18-T.After being digested by BglⅡ,the HPV16L1E7was inserted into the expression vector pQE30,and was transformed into E.coli M15.The recombinant vector was induced by IPTG to express the fusion protein.The antigenicity of HPV16L1E7and the expression level were detected by Western blot.Re -sults:The expression protein could reactivate the anti-L1linear epitope antibody.Conclusion:The HPV16L1E7fusion gene can express the L1E7fusion protein in E.coli sucessfully and at high level,the L1E7takes up above25%of total cell protein.
出处 《山东大学学报(医学版)》 CAS 2003年第2期112-115,共4页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金(39870739) 山东省卫生厅科研基金 山东大学青年基金资助课题
关键词 乳头状瘤病毒 克隆 分子 大肠杆菌 基因表达 Papillomavirus,human Clone,molecular Escherichia coli Gene expression
  • 相关文献

参考文献8

  • 1于修平,Steve A.Jenison.人乳头瘤病毒16型E_7开放读码框编码免疫反应表位的定位[J].病毒学杂志,1990,3(3):245-251. 被引量:3
  • 2卞继峰,于修平,齐眉,王芸,杨海宁,胡海燕,耿昭,赵蔚明,周亚滨,贾继辉,栾怡.HPV16 L1-E7重组腺病毒rAd5 HPV16 L1-E7的构建及克隆表达[J].山东医科大学学报,2000,38(2):113-116. 被引量:13
  • 3Zhou J, Sun XY, Stenzel D J, et al. Expression of vaccinia recombinant HPV16 L1 and L20RF protein in epithelial cells is sufficient for assembly of HPV virion-like particles[J]. J Virol, 1991(B), 185:251.
  • 4Jochmus I, Schafer K, Kaath S, et al. Chimeric virus-like particles of the human papillomavirus type 16 as a prophylactic and therapeutic vaccine [J]. Arch Med Res, 1999, 30:269.
  • 5Franconi R, Di Bonito P, Dibellop F, et al. Plant-derived human papillomavirus 16 E7 oncoprotein induces immmune response and specific tumor protection[J]. Cancer Res, 2002, 62(13):3654.
  • 6de Jong A, O" Neill T, Khan AY, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine[J]. Vaccine, 2002, 20(29-30):3456.
  • 7Gerard CM. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice[J].Clin Cancer Res, 2001, 7(3 Suppl):838s.
  • 8Banks L, Edmords C, Vousden KH. Ability of the HPV16E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells[J].Oncogene, 1990, 5(9):1383.

二级参考文献3

  • 1Muller M,J Virol,1997年,234期,93页
  • 2Zhou J,J Virol.B,1991年,185,251页
  • 3于修平,病毒学报,1990年,3卷,245页

共引文献14

同被引文献26

  • 1卞继峰,于修平,耿昭,卢翌,胡海燕,王晓明.携带双启动子DNA疫苗载体的减毒沙门菌在体内定植及动态变化[J].山东大学学报(医学版),2004,42(5):531-533. 被引量:2
  • 2李鼎锋,刘勇,孙茂盛.初免-加强免疫策略在疫苗研究中的应用[J].微生物学免疫学进展,2006,34(3):65-68. 被引量:4
  • 3Hajishengallis G, Hollingshead S K, Koga T,et al. Mucosal immunization with a Bacterial protein anligen geneticalls Ooupledto Cheolera toxin A2/B subunits [J]. J Immunol, 1995,154: 4322-4332.
  • 4McSorley S J, Xu D, Liew F Y. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters[J]. Infect Immun, 1997, 65(1):171-178.
  • 5Newton S M, Klebba P E, Hofnung M, et al. Studies of the anaerobically induced promoter pnirB and the improved expression of bacterial antigens[J]. Res Microbiol, 1995,146(3):193-202.
  • 6Rocha-Zavaleta L, Pereira-Suarez AL, Yescas G, et al. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology [J]. Viral Immunol, 2003, 16(2):159-68.
  • 7Eiben G L, da Silva D M, Fausch S C, et al. Cervical cancer vaccines: recent advances in HPV research [J]. Viral Immunol, 2003,16(2):111-121.
  • 8Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus(HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin, 2007,57 ( 1 ) :7-28.
  • 9Walboomers JM, Jacobs MV, Manos MM,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1) : 12-19.
  • 10Kimbaner R, Tanb J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 1993,67(12) :6929-6936.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部